PARP Inhibitor Combination Approaches in Prostate Cancer: Interpretation of Clinical Findings and Regulatory Approvals

Expert insight on integrating PARP inhibitor combination therapy into clinical practice for patients with prostate cancer including a downloadable slideset, interactive webcast, and expert commentary.

Share

Program Content

Activities

PARPi Monotherapy in PCa
Single-Agent PARP Inhibitors in Prostate Cancer
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: January 24, 2024

Rationale for PARP Combos in PCa
Leveraging Interdependencies of Targeted Pathways: Rationale for PARPi Combinations
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: January 24, 2024

PARPi Combinations in PCa
PARP Inhibitor/AR Pathway Inhibitor Combination Approaches in Prostate Cancer
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: January 24, 2024

Activities

PARPi in Prostate Cancer
Clinical Findings and Approvals: PARP Inhibitor Strategies in Prostate Cancer
Video
Congratulations: You achieved a completion on 04/09/2022

Released: February 07, 2024

Expires: February 06, 2025

Activities

PARPi in Prostate Cancer
Understanding the Role of PARP Inhibitors in Prostate Cancer: Key Takeaways From a Symposium in San Francisco
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: February 12, 2024

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by educational grants from AstraZeneca; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Merck & Co., Inc., Rahway, NJ, USA.

AstraZeneca

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Merck & Co., Inc., Rahway, NJ, USA